Call 413.540.1234 to
schedule an appointment
CONCERN/EAP: 413.534.2625
CRISIS: 413.733.6661

Health Policy & Advocacy
Resources
Basic InformationMore InformationLatest News
Technology Can Help Patients Facing Routine DecisionsKidneys From Deceased Diabetics Might Ease Organ Shortage: StudyElements of a Patient-Centered Hospital Room IdentifiedCan Tracking Germs in One Hospital Make All Hospitals Safer?Chances of Successful CPR Dwindle as Seniors AgeNew FDA Head Outlines 'Forceful Steps' Against Opioid CrisisChecking Patient's Drug History May Help Curb Opioid AbuseAt Major Teaching Hospitals, Lower Death RatesAmericans Skeptical of Corporate-Backed Health ResearchToo Many Americans Still Go Without Cancer ScreeningsBlack, Hispanic Americans Less Likely to See a NeurologistSome Lead Poisoning Tests May Be FaultyYour Doctor's Age Might Affect Your CareMany U.S. Travelers Skip Measles Shots, Despite Infection RiskPatients Satisfied With Telehealth Primary Care VisitsNearly a Third of Drugs Hit by Safety Issues After FDA ApprovalNo Routine Screening for Thyroid Cancer: Expert PanelPAS: Internet Info Can Lower Parent Trust in Doctors' DiagnosisFDA Warns of Tattoo DangersBystander CPR Not Only Saves Lives, It Lessens Disability: StudyMore Starring Roles for Booze in Kids' Movies, Study FindsMental Health Myths Abound in the U.S.Half of U.S. Docs Get Payments From Drug, Device Industries: StudyAMA Urges Doctors to Talk About Safe Opioid Storage, DisposalRoutine Blood Tests Can Harm Patient CareApril 29 Is National Prescription Drug Take Back DayFDA Warns 14 Companies on Bogus Cancer 'Cures'Price Transparency Intervention Doesn't Cut Lab Test OrdersMost Patients Not Shy About Revealing Sexual OrientationNYC to Raise Cigarette Prices to Highest in the United StatesWearable Devices Increasingly Being Used to Record Health DataPolice-Inflicted Injuries Send 50,000 to ER Annually in U.S.Care Access Worsening for Adults With Psychological DistressIs That Your Doctor Swearing, Drinking on Facebook?AAFP: Educational Videos Created to Boost Adult Vaccine UptakeWeb-Based Platform Better for Delivering Pre-Op InformationAMA: Two Internet Tools Can Help Educate PatientsDoctor Communication Style Key During Bad-News EncountersIs 'Desktop Medicine' Chipping Away at Patient Care?U.S. Blood Supply Safe From Zika Virus, Officials Say'Right-to-Try' Laws: A Patient's Best Last Chance or False Hope?Physicians Finding Ways to Work Around Cost of Rx MedicationsSecond Opinion Yields Different Diagnosis for 1 in 5 PatientsUse of Health Literacy Tools Can Promote Shared Decision MakingMost Americans Favor Larger Health Warnings on Cigarette PacksClimate Change May Cloud Americans' Mental Health: ReportACP Issues Challenge to Cut Task Burden and Put Patients FirstHealth Tip: Talk to Your Doctor About Emotional StrugglesJust 17 U.S. States Require Defibrillators in Some SchoolsFewer Successful Malpractice Claims in U.S., But Higher Payouts
Questions and AnswersLinksBook Reviews
Related Topics

Nearly a Third of Drugs Hit by Safety Issues After FDA Approval

HealthDay News
by -- Robert Preidt
Updated: May 10th 2017

new article illustration

WEDNESDAY, May 10, 2017 (HealthDay News) -- Safety problems emerge with nearly one in three prescription drugs after they've been approved by the U.S. Food and Drug Administration, a new study reveals.

Researchers examined data on drugs approved by the FDA between 2001 and 2010, with follow-up through 2017. The investigators found that 32 percent of the drugs had safety issues after approval.

"That is very rarely a drug withdrawal, but more commonly a black-box warning or drug safety communication issued by the FDA to let physicians and patients know that new safety information has been determined," said study leader Dr. Joseph Ross. He is an associate professor of medicine and public health at Yale University.

Of 222 drugs approved by the agency during the study period, three were withdrawn, 61 received boxed warnings and 59 prompted safety communications, the findings showed.

Drugs most likely to have post-approval safety concerns included biologics, psychiatric drugs and medicines approved through the FDA's accelerated approval process.

The report is timely because the FDA is under pressure to accelerate drug approvals, the study authors noted.

"It shows that there is the potential for compromising patient safety when drug evaluation is persistently sped up," Ross said in a university news release.

At the very least, the study should inform the ongoing debate about pre-market drug evaluation, the researchers suggested.

To assess experimental drugs for safety and effectiveness, the FDA relies on pre-market drug testing and clinical trials. Most of the trials involve fewer than 1,000 patients studied over a period of six months or less. This makes it hard to detect safety issues that might surface once more patients use the drug over a longer time period, the researchers explained.

According to study author Dr. Nicholas Downing, from the department of medicine at Brigham and Women's Hospital, in Boston, "The fact that so many new safety risks are being identified after FDA approval indicates that the FDA is taking its responsibility of ensuring the safety of new drugs throughout their lifetime seriously."

However, "these safety risks emerge, on average, four years after approval. This means that many patients are exposed to these medications before the risks become clear," Downing added in a hospital news release.

Some of those risks included serious skin reactions, liver damage, cancer and even death, the Associated Press reported.

The findings were published May 9 in the Journal of the American Medical Association.

More information

There's more about adverse drug reactions from the American Academy of Family Physicians.